John Gilchrist

John Gilchrist

Auto-generated profile, based on publicly available information

John Gilchrist

Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, 21205, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2016 in Nature
Verified
Journal Article
Open access
PDF file
JOJeremiah D. Osteen
Jeremiah D. Osteen
Volker HerzigVolker Herzig
Volker Herzig
JGJohn Gilchrist
John Gilchrist
JEJoshua J. Emrick
Joshua J. Emrick
CZChuchu Zhang
Chuchu Zhang
DJDavid Julius
David Julius
Voltage-gated sodium (Nav) channels initiate action potentials in most neurons, including primary afferent nerve fibres of the pain pathway. Local anaesthetics block pain through non-specific actions at all Nav channels, but the discovery of selective modulators would facilitate the analysis of individual subtypes of these channels and their contributions to chemical, mechanical, or thermal pain. Here we identify and characterize spider (Heteroscodra maculata) toxins that selectively activate the Nav1.1 subtype, the role of which in nociception and pain has not been elucidated. We use these probes to show that Nav1.1-expressing fibres are modality-specific nociceptors: their activation elicits robust pain behaviours without neurogenic inflammation and produces profound hypersensitivity to mechanical, but not thermal, stimuli. In the gut, high-threshold mechanosensitive fibres also express Nav1.1 and show enhanced toxin sensitivity in a mouse model of irritable bowel syndrome. Together, these findings establish an unexpected role for Nav1.1 channels in regulating the excitability of sensory nerve fibres that mediate mechanical pain.

1 March 2018 in Neuron
Verified
Journal Article
Closed access
CPChristian J. Peters
Christian J. Peters
JGJohn M. Gilchrist
John M. Gilchrist
JTJason Tien
Jason Tien
NBNeville P. Bethel
Neville P. Bethel
LQLijun Qi
Lijun Qi
LJLily Y. Jan
Lily Y. Jan

11 July 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNiraj S. Bende
Niraj S. Bende
SDSławomir Dziemborowicz
Sławomir Dziemborowicz
MMMehdi Mobli
Mehdi Mobli
Volker HerzigVolker Herzig
Volker Herzig
JGJohn Gilchrist
John Gilchrist
FBFrank Bosmans
Frank Bosmans
β-Diguetoxin-Dc1a (Dc1a) is a toxin from the desert bush spider Diguetia canities that incapacitates insects at concentrations that are non-toxic to mammals. Dc1a promotes opening of German cockroach voltage-gated sodium (Nav) channels (BgNav1), whereas human Nav channels are insensitive. Here, by transplanting commonly targeted S3b–S4 paddle motifs within BgNav1 voltage sensors into Kv2.1, we find that Dc1a interacts with the domain II voltage sensor. In contrast, Dc1a has little effect on sodium currents mediated by PaNav1 channels from the American cockroach even though their domain II paddle motifs are identical. When exploring regions responsible for PaNav1 resistance to Dc1a, we identified two residues within the BgNav1 domain II S1–S2 loop that when mutated to their PaNav1 counterparts drastically reduce toxin susceptibility. Overall, our results reveal a distinct region within insect Nav channels that helps determine Dc1a sensitivity, a concept that will be valuable for the design of insect-selective insecticides.

2 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JGJohn Gilchrist
John Gilchrist
SDSamir Das
Samir Das
FPFilip Van Petegem
Filip Van Petegem
FBFrank Bosmans
Frank Bosmans
Significance: Voltage-gated sodium (Na v ) channels are members of a large complex that plays a crucial role in rapid electrical signaling throughout the human body. As prominent members of this complex, β-subunits modify Na v channel function and cause debilitating disorders when mutated. Collectively, the functional and crystallographic results reported in this work uncover intricate interactions of these elements within the Na v -channel signaling complex and establish a key role for β-subunits in shaping Na v 1.2 pharmacology. An important concept emerging from our results is that β-subunits provide exciting opportunities for designing new therapeutic strategies to correct their abnormal behaviors.

15 February 2014
Verified
Book Chapter
Closed access
PDF file
JGJohn Gilchrist
John Gilchrist
BOBaldomero Olivera
Baldomero Olivera
FBFrank Bosmans
Frank Bosmans

31 March 2014 in ACS Chemical Biology
Verified
Journal Article
Open access
JGJohn Gilchrist
John Gilchrist
SDStacey Dutton
Stacey Dutton
MDMarcelo Diaz-Bustamante
Marcelo Diaz-Bustamante
AMAnnie McPherson
Annie McPherson
NONicolas Olivares
Nicolas Olivares
FBFrank Bosmans
Frank Bosmans
Here, we report the discovery of a novel anticonvulsant drug with a molecular organization based on the unique scaffold of rufinamide, an anti-epileptic compound used in a clinical setting to treat severe epilepsy disorders such as Lennox-Gastaut syndrome. Although accumulating evidence supports a working mechanism through voltage-gated sodium (Nav) channels, we found that a clinically relevant rufinamide concentration inhibits human (h)Nav1.1 activation, a distinct working mechanism among anticonvulsants and a feature worth exploring for treating a growing number of debilitating disorders involving hNav1.1. Subsequent structure–activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models. Altogether, our results provide novel molecular insights into the rational development of Nav channel-targeting molecules based on the unique rufinamide scaffold, an outcome that may be exploited to design drugs for treating disorders involving particular Nav channel isoforms while limiting adverse effects.